Approach the Invasive Potential with Hurthle Cell Tumors of Thyroid
To observe the expression of P53, CyclinD1, Ki-67, Galectin-3, COX-2, Bcl-2 and approach their contribution on assessing the invasive potential for Hurthle cell tumors. Seventy-three cases of Hurthle cell tumor were collected for immunohistochemistry staining. The patients were followed up with 8 months to 5 years. Tumors were divided into four grades according to invasion and diameter:(1) extremely low risk (27 cases that less than 2 cm and without invasion), (2) low risk (18 cases that within 2–3.9 cm and without invasion), (3) moderate risk (21 cases that achieve 4 cm and without invasion), (4) high risk (7 cases that with invasion of capsule/vessel in spite of the diameter). Immunostaining presented that all 73 cases were positive with Galectin-3, COX-2 and Bcl-2. For each group, P53 positive were 29.6%, 55.6%, 90.5%, 100.0%; CyclinD1 stained with 7.4%,22.2%,52.4%,100.0% and Ki-67 were 0.0%,5.6%,9.5%,28.6%, respectively. The higher risk of tumor, the more cases that positive expressed P53 and CyclinD1. After following up within 49 patients, two of the recurring cases were positive with P53 and CyclinD1 and one of which was also highly expressed Ki-67. Detecting P53, CyclinD1 and Ki-67 might provide reference for invasive potential assessment with Hurthle cell tumors but not Galectin-3, COX-2 and Bcl-2.
KeywordsHurthle cell tumors Immunohistochemistry P53 CyclinD1 Ki-67
Thanks to all the colleagues in our department for their support.
Ding Li:design and specimen collecting; Jiang Yunhui:pathology diagnosis and specimen collecting; Yang Wan:operate a immunostaining.
Compliance with Ethical Standards
Each of the author has approved the final version of the manuscript and reports no conflicts of interest.
- 1.Hoos A, Stojadinovic A, Singh B, Dudas ME, Leung DHY, Shaha AR, Shah JP, Brennan MF, Cordon-Cardo C, Ghossein R (2002) Clinical significance of molecular expressing profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays [J]. Am J Pathol 160(1):175–183CrossRefPubMedGoogle Scholar
- 7.Ding L, Zou X, Yang W et al (2016) Analyze two cases of encapsulated papillary oncocytic neoplasms (EPONs) of the thyroid [J]. Int J Clin Exp Pathol 9(7):7493–7497Google Scholar
- 11.Anila KR, Nayak N, George PS, Jayasree K (2018) Cytomorphologic spectrum of Hurthle cell lesions of thyroid: a study of 54 cases [J]. Gulf J Oncolog 1(26):6–10Google Scholar
- 15.Petric R, Gazic B, Goricar K et al (2016) Expression of miRNA and occurrence of distant metastases in patients with Hurthle cell carcinoma [J]. Int J Endocrinol 8945247:2016Google Scholar
- 17.Gopal RK, Kübler K, Calvo SE, Polak P, Livitz D, Rosebrock D, Sadow PM, Campbell B, Donovan SE, Amin S, Gigliotti BJ, Grabarek Z, Hess JM, Stewart C, Braunstein LZ, Arndt PF, Mordecai S, Shih AR, Chaves F, Zhan T, Lubitz CC, Kim J, Iafrate AJ, Wirth L, Parangi S, Leshchiner I, Daniels GH, Mootha VK, Dias-Santagata D, Getz G, McFadden DG (2018) Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma [J]. Cancer Cell 34(2):242–255CrossRefGoogle Scholar
- 18.Giaginis C, Alexandrou P, Delladetsima I, Karavokyros I, Danas E, Giagini A, Patsouris E, Theocharis S (2016) Clinical significance of Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human malignant and benign thyroid lesions [J]. Pathol Oncol Res 22(1):189–196CrossRefGoogle Scholar
- 23.Liang M, Zhao J (2018) Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis [J]. Eur Rev Med Pharmacol Sci 22(16):5134–5139Google Scholar